Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neurosense Therapeutics Ltd (NRSN)

Neurosense Therapeutics Ltd (NRSN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,022
  • Shares Outstanding, K 32,557
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,210 K
  • EBIT $ -3 M
  • EBITDA $ -10 M
  • 60-Month Beta 1.70
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.54
  • Most Recent Earnings $-0.06 on 04/07/25
  • Next Earnings Date 06/30/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6300 +31.75%
on 03/24/26
1.0500 -20.95%
on 03/16/26
-0.0200 (-2.35%)
since 03/02/26
3-Month
0.6300 +31.75%
on 03/24/26
1.1000 -24.55%
on 01/14/26
+0.0501 (+6.42%)
since 01/02/26
52-Week
0.6300 +31.75%
on 03/24/26
2.6000 -68.08%
on 06/12/25
-0.0886 (-9.65%)
since 04/02/25

Most Recent Stories

More News
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements

CAMBRIDGE, Mass. , April 3, 2026 /PRNewswire/ --  NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments...

NRSNW : 0.2000 (unch)
NRSN : 0.8300 (+9.21%)
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

CAMBRIDGE, Mass. , March 31, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments...

NRSN : 0.8300 (+9.21%)
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout

CAMBRIDGE, Mass. , March 24, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...

NRSN : 0.8300 (+9.21%)
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference

Dr. Christian Lunetta to Present "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial"

NRSNW : 0.2000 (unch)
NRSN : 0.8300 (+9.21%)
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower functional...

NRSNW : 0.2000 (unch)
NRSN : 0.8300 (+9.21%)
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

CAMBRIDGE, Mass. , March 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...

NRSNW : 0.2000 (unch)
NRSN : 0.8300 (+9.21%)
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS

CAMBRIDGE, Mass. , Feb. 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...

NRSNW : 0.2000 (unch)
NRSN : 0.8300 (+9.21%)
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition

Strengthens Global IP Portfolio for PrimeC Through 2042

NRSN : 0.8300 (+9.21%)
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease

CAMBRIDGE, Mass. , Jan. 21, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...

NRSNW : 0.2000 (unch)
NRSN : 0.8300 (+9.21%)
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026

NRSNW : 0.2000 (unch)
NRSN : 0.8300 (+9.21%)

Business Summary

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company. It focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, such as ALS, Alzheimer's and Parkinson's disease. NeuroSense Therapeutics Ltd. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 0.9397
2nd Resistance Point 0.8897
1st Resistance Point 0.8599
Last Price 0.8300
1st Support Level 0.7801
2nd Support Level 0.7301
3rd Support Level 0.7003

See More

52-Week High 2.6000
Fibonacci 61.8% 1.8475
Fibonacci 50% 1.6150
Fibonacci 38.2% 1.3825
Last Price 0.8300
52-Week Low 0.6300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.